IL319272A - Rovel fusion חלבון ספציפי עבור cd137 ו-cd228 - Google Patents
Rovel fusion חלבון ספציפי עבור cd137 ו-cd228Info
- Publication number
- IL319272A IL319272A IL319272A IL31927225A IL319272A IL 319272 A IL319272 A IL 319272A IL 319272 A IL319272 A IL 319272A IL 31927225 A IL31927225 A IL 31927225A IL 319272 A IL319272 A IL 319272A
- Authority
- IL
- Israel
- Prior art keywords
- fusion protein
- protein specific
- novel fusion
- novel
- specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263408634P | 2022-09-21 | 2022-09-21 | |
| US202263413174P | 2022-10-04 | 2022-10-04 | |
| US202363496463P | 2023-04-17 | 2023-04-17 | |
| PCT/US2023/074629 WO2024064713A1 (en) | 2022-09-21 | 2023-09-20 | Novel fusion protein specific for cd137 and cd228 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL319272A true IL319272A (he) | 2025-04-01 |
Family
ID=88412496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL319272A IL319272A (he) | 2022-09-21 | 2023-09-20 | Rovel fusion חלבון ספציפי עבור cd137 ו-cd228 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP4590695A1 (he) |
| JP (1) | JP2025532652A (he) |
| KR (1) | KR20250071257A (he) |
| CN (1) | CN120513253A (he) |
| AU (1) | AU2023347921A1 (he) |
| CA (1) | CA3268207A1 (he) |
| CO (1) | CO2025003722A2 (he) |
| IL (1) | IL319272A (he) |
| MX (1) | MX2025003304A (he) |
| PE (1) | PE20251544A1 (he) |
| TW (1) | TW202428603A (he) |
| WO (1) | WO2024064713A1 (he) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025175123A1 (en) * | 2024-02-16 | 2025-08-21 | Seagen Inc. | Methods of treating cancer using fusion proteins specific for cd137 and cd228 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US6080560A (en) | 1994-07-25 | 2000-06-27 | Monsanto Company | Method for producing antibodies in plant cells |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| CN1170543C (zh) | 1998-06-08 | 2004-10-13 | 弗·哈夫曼-拉罗切有限公司 | PEG-IFN-α和三唑核苷在治疗慢性丙型肝炎中的用途 |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| EP1377306A1 (en) | 2001-03-09 | 2004-01-07 | Dyax Corp. | Serum albumin binding moieties |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| WO2007038619A2 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| SG11201504676VA (en) | 2012-12-14 | 2015-07-30 | Omt Inc | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same |
| AU2016258952C1 (en) | 2015-05-04 | 2020-12-24 | Pieris Pharmaceuticals Gmbh | Proteins specific for CD137 |
| RU2754466C2 (ru) * | 2015-05-18 | 2021-09-02 | ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ | Слитый полипептид с противораковой активностью |
| LT3830120T (lt) * | 2018-07-31 | 2023-07-10 | Pieris Pharmaceuticals Gmbh | Naujas sulietas baltymas specifinis cd137 ir pd-l1 atžvilgiu |
| WO2020163225A1 (en) * | 2019-02-05 | 2020-08-13 | Seattle Genetics, Inc. | Anti-cd228 antibodies and antibody-drug conjugates |
-
2023
- 2023-09-20 WO PCT/US2023/074629 patent/WO2024064713A1/en not_active Ceased
- 2023-09-20 EP EP23789849.9A patent/EP4590695A1/en not_active Withdrawn
- 2023-09-20 IL IL319272A patent/IL319272A/he unknown
- 2023-09-20 CA CA3268207A patent/CA3268207A1/en active Pending
- 2023-09-20 TW TW112135862A patent/TW202428603A/zh unknown
- 2023-09-20 AU AU2023347921A patent/AU2023347921A1/en active Pending
- 2023-09-20 JP JP2025517027A patent/JP2025532652A/ja active Pending
- 2023-09-20 KR KR1020257012767A patent/KR20250071257A/ko active Pending
- 2023-09-20 CN CN202380080191.4A patent/CN120513253A/zh active Pending
- 2023-09-20 PE PE2025000649A patent/PE20251544A1/es unknown
-
2025
- 2025-03-20 MX MX2025003304A patent/MX2025003304A/es unknown
- 2025-03-21 CO CONC2025/0003722A patent/CO2025003722A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN120513253A (zh) | 2025-08-19 |
| EP4590695A1 (en) | 2025-07-30 |
| CA3268207A1 (en) | 2024-03-28 |
| MX2025003304A (es) | 2025-06-02 |
| TW202428603A (zh) | 2024-07-16 |
| KR20250071257A (ko) | 2025-05-21 |
| PE20251544A1 (es) | 2025-06-05 |
| WO2024064713A1 (en) | 2024-03-28 |
| AU2023347921A1 (en) | 2025-03-20 |
| JP2025532652A (ja) | 2025-10-01 |
| CO2025003722A2 (es) | 2025-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL284687A (he) | חלבוני איחוי חדשים ספציפיים ל- cd137 ו- gpc3 | |
| ZA202100125B (en) | Novel fusion protein specific for cd137 and pd-l1 | |
| EP3943512A4 (en) | FUSION PROTEIN TO ENHANCE GENE EDITING AND USE | |
| IL316697A (he) | חלבוני איחוי cd200 חדשים | |
| IL321797A (he) | חלבונים מאוחים il-12 fc | |
| GB202307936D0 (en) | Fusion protein | |
| GB202307932D0 (en) | Fusion protein | |
| IL315354A (he) | חלבון איחוי אינסולין | |
| GB202105044D0 (en) | Fusion protein | |
| EP4423260A4 (en) | Truncated and fusion proteins | |
| EP4435002A4 (en) | MODIFIED PROTEIN OR POLYPEPTIDE | |
| GB202416138D0 (en) | Fusion protein | |
| GB202218084D0 (en) | Fusion proteins | |
| EP4169938A4 (en) | RECOMBINANT PROTEIN PURIFICATION METHOD | |
| HK40060297A (en) | Novel fusion proteins specific for cd137 and gpc3 | |
| GB202402535D0 (en) | Fusion proteins | |
| CA3289101A1 (en) | Fusion protein | |
| CA3282205A1 (en) | Fusion protein | |
| GB202312969D0 (en) | Modified proteins | |
| AU2024360793A1 (en) | Insulin-fc fusion proteins | |
| PT3830120T (pt) | Nova proteína de fusão específica para cd137 e pd-l1 | |
| AU2026904553A0 (en) | Fusion proteins | |
| IL320073A (he) | שיטה להגדלת ביטוי חלבון רקומביננטי | |
| GB202217084D0 (en) | Therapeutic fusion proteins | |
| CA3299830A1 (en) | Modified proteins |